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Abstract. Primaquine phosphate has been used for preventing relapse of Plasmodium vivax and P. ovale malaria
since the early 1950s, based on its ability to kill latent (hypnozoite) and developing liver stages of these parasites. There
are three uses for primaquine in malaria: radical cure of established infection with P. vivax or P. ovale malaria;
presumptive anti-relapse therapy (PART; terminal prophylaxis) in persons with extensive exposure to these parasites;
and primary prophylaxis against all malaria species. All persons for whom primaquine is being considered must have a
glucose-6-phosphate dehydrogenase (G6PD) enzyme level checked before use, and persons who have a deficiency of
G6PD must not take primaquine for prophylaxis or PART. The recommended adult dose for PART based on clinical
trials and expert opinion is 30 mg base daily for 14 days, started on return from a malarious region and overlapping with
a blood schizonticide. The adult dose for primary prophylaxis is 30 mg daily begun 1 day before travel and continued
for 7 days after return. This review will examine the evidence for these recommendations.
SUMMARY
Indications. Presumptive anti-relapse therapy (terminal
prophylaxis) in persons heavily exposed to Plasmodium vivax
or P. ovale.
Prophylaxis (causal), as a second line agent, for prevention
of all Plasmodium species (not currently Food and Drug Ad-
ministration [FDA]-approved for this indication).
Radical cure in persons with a confirmed bloodstream in-
fection with P. vivax or P. ovale.
Dosing. Note: 15 mg base 26.3 mg of the phosphate salt;
doses for all anti-malarials in this document are expressed in
the base form. Glucose-6-phosphate dehydrogenase (G6PD)
testing must be performed before a patient takes primaquine.
Adult. Presumptive anti-relapse therapy: 30 mg daily for 14
days, based on clinical trials data (A-II†) and current expert
opinion (C-III).‡ Dosing should overlap with a blood schizon-
ticide.
Prophylaxis: 30 mg daily started 1 day before travel, taken
daily during travel and for 7 days after travel (A-I).
Radical cure: 30 mg daily for 14 days to overlap with the
blood schizonticide agent (A-I).
Pediatric. Presumptive anti-relapse therapy: 0.5 mg/kg (up
to a maximum of 30 mg) daily for 14 days (B-III).
Prophylaxis: 0.5 mg/kg daily (up to a maximum 30 mg)
started 1 day before travel, taken daily during travel and for
7 days after travel (B-I for use in children 7 years of age and
older; B-III for use in children 6 years of age and younger).
Radical cure: 0.5 mg/kg daily (up to a maximum 30 mg) for
14 days to overlap with the blood schizonticide agent (A-I).
Efficacy. Presumptive anti-relapse therapy: high (∼95%
and greater) at doses of 30 mg daily for 14 days (in combina-
tion with a blood schizonticide such as chloroquine). Al-
though 15 mg daily (0.25 mg/kg/d) for 14 days effectively
prevents relapse with P. vivax from many areas of the world,
some strains of P. vivax (principally found in Southeast Asia
and South Pacific) may not be eradicated at this dosage.
Prophylaxis: clinical trials indicate > 85% protective effi-
cacy against P. falciparum and primary P. vivax infections at
a dose of 30 mg daily.
Radical cure: high (> 90%) with medication compliance
and 30 mg daily equivalent dosing.
Adverse drug reactions. Most common mild/moderate ad-
verse drug reactions (ADRs): abdominal pain, nausea, vom-
iting.
Severe: hemolysis in persons with G6PD deficiency. Met-
hemoglobinemia occurs, but is not reported to be clinically
significant at dosages used for prophylaxis. In studies, 0–2%
of persons have reported a severe reaction and 0–2% have
discontinued prophylaxis because of ADRs.
Contraindications.
• G6PD deficiency
• NADH methemoglobin reductase deficiency
• Known hypersensitivity to primaquine or related drugs
(e.g., iodoquinol)
• Persons receiving treatment with other potentially hemo-
lytic drugs
• Pregnancy (even if a pregnant woman is G6PD normal, the
fetus may not be)
• The packaging label states that primaquine is contraindi-
cated in persons with illnesses manifest by a tendency to
granulocytopenia (lupus erythematosus and rheumatoid ar-
thritis), but data are lacking on this association at dosages
used in malaria chemoprophylaxis.
Precautions. Must have G6PD testing performed before us-
ing primaquine.
Drug interactions. Primaquine 30 mg/day has caused severe
methemoglobinemia in HIV-infected individuals when used
for prophylaxis of Pneumocystis jiroveci (previously P. cari-
nii) pneumonia, especially in those currently or recently tak-
ing dapsone.
Use during pregnancy. Contraindicated.
Use during breastfeeding. Use only if infant is tested for
G6PD deficiency and has normal enzyme levels.
Use in children. May be used in children of any age.
* Address correspondence to David R. Hill, MD, DTM&H, National
Travel Health Network and Centre and London School of Hygiene &
Tropical Medicine Mortimer Market Centre, Capper Street, London
WC1E 6AU, UK. E-mail: david.hill@uclh.org
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† Infectious Diseases Society of America-United States Pub-
lic Health Service Grading System for ranking recommenda-
tions in clinical guidelines.1 Strength of recommendation: A,
good evidence to support a recommendation for use; B, mod-
erate evidence to support a recommendation for use; C, poor
evidence to support a recommendation; D, moderate evi-
dence to support a recommendation against use; E, good evi-
dence to support a recommendation against use. Quality of
evidence: I, evidence from one or more properly randomized,
controlled trials; II, evidence from one or more well-designed
clinical trials, without randomization; from cohort or case-
controlled analytic studies (preferably from > 1 center); from
multiple time-series; or from dramatic results from uncon-
trolled experiments; III, evidence from opinions of respected
authorities, based on clinical experience, descriptive studies,
or reports of expert committees.
‡ 15 mg daily for 14 days is the current FDA-approved
regimen; 30 mg daily for 14 days is not currently an FDA-ap-
proved regimen, although clinical trials data (A-II) and current
expert opinion (C-III) support the use of the higher dose.
 Mild/moderate ADRs enumerated if reported in at least
two studies at > 2% frequency; ordered according to number
of studies that reported this ADR.
 Severe ADRs may be defined in various ways in different
studies, but include ADRs interfering with activities of daily
living or prompting the seeking of medical attention. Severe
ADRs may also include any of the reactions listed under mild
to moderate ADRs if they are severe in intensity.
INTRODUCTION
Since its approval in 1952 by the FDA, primaquine has
been the only available agent capable of preventing relapse
after infection with Plasmodium vivax and P. ovale malaria
species. This has been termed radical cure. Primaquine, an
8-aminoquinoline, kills latent (hypnozoite) and developing
liver stages of these plasmodia. At therapeutic doses, pri-
maquine also exerts lethal activity against the asexual blood
stages of P. vivax but not those of P. falciparum.2–4 When
primaquine is given presumptively in conjunction with a
blood stage prophylaxis agent to an individual who has trav-
eled to an area of the world where P. vivax or P. ovale occurs,
therapy is called terminal prophylaxis or “presumptive anti-
relapse therapy” (PART). PART is a term that more accu-
rately defines its role and is the term that will be used. Some
health authorities recommend that PART be administered to
individuals after substantial risk of infection with P. vivax or
P. ovale,5,6 although a consensus defining “substantial” risk is
lacking.
Primaquine may also be used as a “primary” prophylactic
because it prevents primary parasitemia by all species of ma-
laria by destroying these parasites in the liver before they
reach the bloodstream and cause disease.7 Prophylactic
agents that prevent the blood stage infection by killing devel-
oping liver stage parasites are referred to as “causal” prophy-
lactics. Primaquine may cause lethal hemolysis when admin-
istered to individuals deficient in G6PD. All persons who
receive primaquine are required to have testing for G6PD.
Primaquine should not be administered for prophylaxis in
individuals deficient in G6PD.
Primaquine’s mechanism of action is poorly understood,
but it severely disrupts the metabolic processes of plasmodial
mitochondria. The anti-malarial activity is probably attribut-
able to interference with the function of ubiquinone as an
electron carrier in the respiratory chain. Another potential
mechanism of action against plasmodia is the production of
highly reactive metabolites that generate toxic intracellular
oxidative potentials.
RECOMMENDED USES AND DOSING
OF PRIMAQUINE
There are three uses for primaquine in malaria: prophy-
laxis, presumptive anti-relapse therapy (terminal prophylaxis)
for P. vivax and P. ovale, and radical cure after P. vivax or P.
ovale clinical disease. The focus of this review is the use of
primaquine for prophylaxis and PART. Note: 15 mg base 
26.3 mg of the phosphate salt; doses for all anti-malarials in
this document are expressed in the base form. G6PD testing
must be performed before prescribing primaquine.
Prophylaxis. Prophylaxis prevents primary parasitemia (as
opposed to PART that is used to prevent relapse of P. vivax
and P. ovale by killing hypnozoites). When primaquine is
used as prophylaxis, a dose of 30 mg daily (adult dose) be-
ginning 1 day before exposure and continuing for 1 week after
departure from an area with malaria is recommended.5–7 For
adults < 60 kg and children, the Centers for Disease Control
and Prevention (CDC)-recommended dosage is 0.5 mg/kg/d
(to a maximum daily dose of 30 mg).5
PART (terminal prophylaxis). PART constitutes presump-
tive therapy to prevent relapse by P. vivax and P. ovale by
killing liver stage hypnozoites. For both historical and safety
considerations in the era before G6PD testing was available,
the current FDA-approved dose is 15 mg daily for 14 days.
However, P. vivax strains acquired in Papua (Indonesian New
Guinea), areas of Oceania, and some other parts of the world
require a higher dose of primaquine to prevent relapse. To
achieve reliable eradication of parasites and with G6PD test-
ing available, the CDC has recommended an increase in dose
from 15 to 30 mg daily for 14 days for adults.5 Expert opinion
and clinical trials data support this recommendation although
clinicians should be aware that the 30-mg daily dose is not
FDA approved. The pediatric dose has also been increased
from 0.25 to 0.5 mg/kg once daily (to a maximum of 30 mg).
To decrease the risk of clinical failure in individuals weighing
> 70 kg, the duration of treatment with 30 mg daily can be
extended to achieve a total dose of 6 mg/kg, especially if the
infection was acquired in an area of known tolerance to stan-
dard primaquine therapy.
Dosing should coincide with the last 2 weeks of chloro-
quine, mefloquine, or doxycycline prophylaxis or initiated
during the final week of atovaquone-proguanil prophylaxis.
Radical cure. Primaquine used in conjunction with an ef-
fective blood stage schizonticide, such as chloroquine, for the
treatment of a symptomatic patient with P. vivax or P. ovale
malaria is termed radical cure. Used in this way, primaquine
will prevent relapse from dormant liver stage or hypnozoite
forms of P. vivax and P. ovale parasites. The doses of pri-
maquine are the same as for PART above. If the results of
G6PD testing return in time and the patient is found to be
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G6PD normal, primaquine should be initiated to overlap with
some portion of the blood stage treatment of these species.
EFFICACY AND EFFECTIVENESS
Prophylaxis (Table 1). In clinical studies using experimen-
tal challenge with infectious sporozoites, the timing of pri-
maquine dosing proved critical to protective efficacy. Single
doses of 30 mg given during days 1 or 3 after sporozoite
injection were effective in preventing malaria, but lower
amounts of primaquine and any dose given before or after
that window were not reliably effective8 (although very high
doses, e.g., 120–180 mg, were effective when given just before
challenge).9 Similarly, a single 45-mg dose given alone or with
chloroquine before or on the day of experimental challenge
with P. falciparum did not have a causal prophylactic effect.10
For daily dosing regimens, early studies showed less than op-
timal efficacy at 15 mg/d, whereas 30 mg/d provided good
efficacy.2,8,10
More recently, a thrice weekly regimen of 15 mg pri-
maquine in Kenyan children showed no protective efficacy
against P. falciparum,11 and an alternate day regimen of 0.5
mg/kg in Indonesia proved 74% and 90% effective against P.
falciparum and P. vivax, respectively.12 All of these data point
to an adult regimen of 30 mg daily for the prevention of
malaria.
A number of studies conducted in the past 10 years exam-
ined daily primaquine (30 mg or an ∼0.5-mg/kg dose in chil-
dren) for primary prophylaxis in populations semi-immune
and non-immune to malaria. A randomized, double-blinded
placebo-controlled trial in Indonesian migrants to Papua re-
ported protective efficacy of 95% (95% CI: 61–99%) against
P. falciparum and 90% (95% CI: 65–99%) against P. vivax.13
In a randomized, placebo-controlled trial among Kenyan chil-
dren, 0.5 mg/kg/d was 85% (95% CI: 68–93%) effective for
prevention of P. falciparum parasitemia.11 In non-immune
Colombian soldiers, a randomized, double-blinded placebo-
controlled trial calculated protective efficacy at 94% (95% CI:
78–99%) for P. falciparum and 85% (95% CI: 57–95%) for P.
vivax.14 The authors of the Colombian study later combined
chloroquine 300 mg weekly with daily primaquine (30 mg/d)
to “improve the efficacy of primaquine for malaria prophy-
laxis.”15 However, protective efficacy for the combination
was not appreciably improved: 88% (95% CI: 76–94%) effec-
tive (89% against P. falciparum and 88% against P. vivax).15
Another randomized placebo-controlled trial in non-immune
migrants to Papua showed protective efficacy of 93% (95%
CI: 71–98%); 88% for P. falciparum and 92% for P. vivax.16
A limitation with each of these studies was the inability to
continue follow-up after prophylaxis to look for late relapse
(because the subjects lived in areas of high risk).17 However,
the early experimental trials did follow subjects for many
months after challenge without evidence of relapse. Arnold
and others2 gave 30 mg of primaquine to volunteers on days
−1, 0, and 1 though 6 after challenge with the Chesson strain
of P. vivax. None of the 10 persons challenged developed
vivax malaria when followed for a range of 190–450 days. This
suggests that not only does primaquine have causal prophy-
lactic activity, but that it will also prevent development of
hypnozoites of P. vivax.
Although no severe falciparum malaria occurred among
parasitemic subjects during the evaluation of primaquine pro-
TABLE 1
Efficacy of primaquine for primary prophylaxis
Country/population Study type Dosage/sample size (n)
Duration of
prophylaxis Efficacy (95% CI)
USA/American
volunteers10
Experimental challenge 15 mg/d (n  3)
30 mg/d (n  3)
45 mg/d (n  1)
6 days after
experimental
infection
P. falciparum infection in:
1/3 on 15 mg/d
0/3 on 30 mg/d
0/1 on 45 mg/d
USA/American
volunteers2
Experimental challenge 10 mg/d (n  10)
15 mg/d (n  10)
30 mg/d (n  10)
6 days after
experimental
infection
P. vivax infection in:
3/10 on 10 mg/d
2/10 on 15 mg/d
0/10 on 30 mg/d
USA/American
volunteers8
Experimental challenge 30 mg/d (n  5) 6 days following
experimental
infection
P. falciparum infection in:
0/5 on 30 mg/d
Papua (Indonesian
New Guinea)/
non-immune
migrants16
Randomized, open label
placebo-controlled
trial
30 mg/d
(n  97)
20 weeks 93% overall (71%–98%)
88% P. falciparum (48%–97%)
92% P. vivax (37%–99%)
Papua/non-immune
migrants12
Non-randomized open label 30 mg every other
day (n  54)
16–19 weeks 74% P. falciparum
90% P. vivax
Kenya/children11 Randomized, placebo-controlled,
double-blind
a. 0.5 mg/kg 3 d/week
(n  40)
b. 0.5 mg/kg/d
(n  32)
11 weeks
11 weeks
0% efficacy against P. falciparum
85% (68%–93%) P. falciparum
parasitemia; 83% (50%–94%)
P. falciparum clinical malaria
Papua/non-immune
migrants13
Randomized, placebo-controlled,
double-blind
30 mg/d (n  126) 52 weeks 94.5% (57%–99%) P. falciparum
90.4% (58%–98%) P. vivax
Colombia/non-immune
soldiers14
Randomized, placebo-controlled,
double-blind
30 mg/d (n  122) 16 weeks 94% (78%–99%) P. falciparum
85% (57%–95%) P. vivax. (note:
counted symptomatic malaria
cases only, not all parasitemias)
Ethiopia/Israeli
travelers19
Prospective observational 15–30 mg/d (n  106) 2–3 weeks 5.7% infected with malaria; 4 P.
falciparum, 1 P. vivax, 1 both
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phylaxis, some authorities are concerned that severe P. falci-
parum malaria could occur if there is primaquine failure,18
because of the lack of blood schizonticidal activity of the drug
against falciparum parasites.
A study reported the effectiveness of daily 15 mg of pri-
maquine (30 mg for those > 70 kg) for primary prophylaxis in
non-immune Israeli travelers.19 Primaquine was more effec-
tive than mefloquine or doxycycline in preventing malaria
caused by P. vivax, with post-travel infection rates for all
species of malaria 6%, 52%, and 53%, respectively. The me-
floquine failures were all caused by late occurrences of P.
vivax, and in the doxycycline group, no travelers completed
the post-travel 4-week course.
Prophylaxis is not currently included as an approved la-
beled use of primaquine. Nonetheless, the drug offers impor-
tant advantages to travelers departing on short notice or for
travel that has only a brief risk (given its relatively short
post-travel dosing). Unfortunately, obtaining confirmation of
adequate G6PD levels in individuals before prescribing pri-
maquine requires phlebotomy and can take up to 1 week or
longer. Nevertheless, primaquine for prophylaxis in G6PD-
normal, non-pregnant travelers can be recommended as an
alternative when other chemoprophylactic agents are inap-
propriate or contraindicated.5,6,20
PART (terminal prophylaxis) and radical cure. Primaquine
is usually used to prevent relapse of P. vivax or P. ovale, i.e.,
to kill developing or dormant liver stages of a confirmed in-
fection (radical cure) or as presumptive therapy to prevent
relapse of suspected or possible infection. The majority of P.
vivax and P. ovale cases occur > 2 months after return from
travel, even in persons who take appropriate malaria chemo-
prophylaxis,21 and could be prevented by PART with pri-
maquine. While there is reasonable consensus among experts
that PART should be used in those with “intense” or “sig-
nificant” exposure, there is no consensus as to what consti-
tutes an intense or significant exposure. There is agreement
that most travelers do not need PART because the overall
risk of developing malaria caused by P. vivax or P ovale is
low, and the requirement to screen for G6PD deficiency be-
fore prescribing primaquine makes its use impractical for
many travelers. PART should be considered for persons who
have resided for prolonged periods (e.g., 6 months or more)
in high-risk areas or who experience intense exposure to P.
vivax such as has been described in rafters on the Omo River
in Ethiopia19 or in travelers to Papua New Guinea.22
To put imported malaria into perspective, for the years
1998 through 2004, there were 9,491 cases of malaria reported
in the United States;23–29 4,574 (48.2%) of these were caused
by P. falciparum, 2,790 were caused by P. vivax (29.4%), 373
(3.9%) were caused by P. malariae, and 260 (2.7%) were
caused by P. ovale. In the remaining cases, the species was not
determined. Of these cases, there were 38 deaths attributable
to P. falciparum, 1 to a mixed P. falciparum/P. malariae in-
fection, 2 to P. ovale, 1 to P. vivax, and in 2 cases, the species
could not be determined. The overall case fatality rate has
been estimated by the CDC to be 0.06% for P. vivax, 0.3% for
P. ovale and P. malariae, and 1.3% for P. falciparum.30
Until recently, the most widely accepted and FDA-
approved regimen of primaquine in PART was 15 mg daily
for 14 days.31,32 An alternative regimen of 30 mg daily for 14
days had been used when so-called “tolerant” strains of P.
vivax (mostly from Southeast Asia or Oceania) were sus-
pected.31 While certain strains of P. vivax have been termed
primaquine-tolerant or -resistant (i.e., not eradicated by the
15-mg dose), it is more likely that these strains represent a
priori biologic differences in sensitivity to primaquine rather
than true development of tolerance or resistance to pri-
maquine.
From the beginning of experimental work using the Ches-
son strain of P. vivax (isolated from an American soldier in
New Guinea during the Second World War)33 and the St.
Elizabeth strain of P. vivax (from temperate United States), a
marked difference in response to primaquine was ob-
served.34–36 For elimination of the Chesson strain, a dose of
22.5 to 30 mg/d of primaquine for 14 days was required; 15
mg/d was not effective.34,37 However, 15 mg/d of primaquine
for 14 days eliminated the St. Elizabeth strain and later the
Korean strain in US service personnel during the Korean
War, although treatment of the Korean strain was always
combined with chloroquine.35,36 The decision to use 15 mg/d
for 14 days in the early 1950s was based on the need for a dose
that could be given safely to returning Korean War African
American soldiers. Individuals of African descent have a
higher likelihood of G6PD deficiency than most groups of
whites, although their G6PD impairment tends to be mild.
With the finding that the hemolytic anemia induced by pri-
maquine was usually dose dependent, 15 mg/d was chosen as
a dose that could be given to all US service personnel without
concern that there would life-threatening hemolysis in the
African-American soldiers (see section on Safety/Toler-
ability).
FDA licensure of primaquine in 1952 was based on the
need to prevent relapsing P. vivax malaria in returning
Korean war veterans, the finding from clinical trials establish-
ing that the 15-mg daily dose could be safely given with-
out medical supervision to African Americans who might
develop hemolytic anemia with higher doses of primaquine
and the knowledge that 15 mg daily for 14 days was effica-
cious against Korean strains of P. vivax.34,36,38,39 Therefore,
safety concerns, rather than efficacy against all strains of P.
vivax, led to the licensure of the 15 mg daily for a 14-day
regimen.
It is important to recognize that chloroquine or quinine
have been shown to be required for the therapeutic efficacy of
primaquine for the eradication of the hypnozoite once it has
been established.37 In a remarkable series of experimental
infections with the Chesson strain of P. vivax, 15 mg daily for
14 days of primaquine when given 2 days after completion of
a curative course of quinine (a short-acting drug) for the ini-
tial blood stage infection led to a cure rate of only 21% (4/19;
15 relapsed between 32 and 92 days). When the same regimen
of primaquine was given concurrently with quinine or chlo-
roquine, cure was seen in 95% (18/19) and 74% (14/19), re-
spectively. These data generated 50 years ago require addi-
tional investigation, but practically, primaquine may exert its
beneficial effect for PART or radical cure when combined
with a 4-amino-quinoline drug such as chloroquine. Impor-
tantly, the mass administration of primaquine to returning
Korean War veterans during the 1951–1952 trans-Pacific
crossings was always accompanied by chloroquine. At the
time, the thinking was to give chloroquine for the residual
blood stages and primaquine for the hypnozoite. Two drugs
were being administered for two indications with no thought
of potentiation or synergy. This potential for synergy has
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never been studied for primaquine with mefloquine, doxycy-
cline, or atovaquone/proguanil.
Failure of standard primaquine therapy (15 mg daily for 14
days) to prevent relapse has been reported from the Solomon
Islands,40–43 Southeast Asia,44–48 Brazil,49–51 Colombia,52
Guyana,53 Guatemala,54 Somalia,55 Ethiopia,56,57 Afghani-
stan58,59 and elsewhere.22,60–64 Because supervised compli-
ance was not confirmed in these studies, these reports may
not all represent failures of the 15-mg/d regimen. As ex-
amples, among US troops in Somalia who took PART, 43%
relapsed, but compliance was not supervised and was self-
reported,55 and in a cohort of US soldiers with P. vivax ma-
laria from Afghanistan, only 38% were compliant with
PART.59 Although a study from the Solomon Islands found
no relapse during 1 year of follow-up subsequent to treatment
with either a 15- or 22.5-mg daily regimen of primaquine,65 a
regimen of 22.5 mg daily was superior to the 15-mg regimen
in Thailand.47 Based on these findings as well as detailed
clinical studies of the Chesson strain of P. vivax, experts have
recommended the 30-mg adult daily regimen for radical cure
of P. vivax malaria acquired in Southeast Asia or Oce-
ania.48,66,67 Last, there was a higher risk of relapse after stan-
dard primaquine therapy (equivalent to 15 mg daily) among
subjects weighing > 70 kg, and higher doses equivalent to the
30-mg daily regimen of primaquine have been recommended
for such individuals.51,56,68
After assessment of these clinical studies and the historical
findings of a variable response to the 15-mg daily dose, the
CDC has now recommended that 30 mg/d for 14 days be the
standard dose for PART and radical cure.5 Because of the
possibility of decreased effectiveness in persons > 70 kg be-
cause of sub-therapeutic dosing, clinicians can consider ex-
tending the duration of PART in these individuals beyond 14
days targeting a total dose of 6 mg/kg.67 A daily dose of > 30
mg is not recommended because the safety of higher daily
doses is not proven.
To avoid drug-induced hemolysis, a regimen of 45 mg
weekly (adult dose) for 8 weeks has been considered when a
person has partial G6PD deficiency.40,69 Both the 45- and
30-mg regimens have proven to be effective treatment against
strains of P. vivax that were not killed by standard therapeutic
regimens.18,34,42,70 The alternative dosing regimen of 45 mg
primaquine once weekly combined with weekly chloroquine
for 8 weeks was introduced in the early 1960s by the US
military.40 Weekly dosing made supervised therapy feasible
and improved compliance over the standard primaquine regi-
men given daily for 14 days. Studies performed in persons
known to be moderately G6PD-deficient showed that the 45-
mg weekly dose could be given with acceptable toxicity, al-
though the data is limited and clinically apparent hemolytic
anemia was seen. These observations evolved to a recommen-
dation that the weekly dosing could be given to those who are
G6PD-deficient. However, this weekly dosing regimen is not
FDA approved, the data to support efficacy are limited, and
safety data in G6PD-deficient persons, especially in those
who have other than the mild, A-phenotype, are not known.
Primaquine for PART in a known G6PD-deficient individual
is not recommended. Use of primaquine for radical cure in a
known G6PD-deficient individual should be used only after a
careful risk/benefit assessment and under strict medical su-
pervision.
A shortened course of primaquine for radical cure would
improve effectiveness (lower cost, greater availability, greater
compliance).71 Earlier non-controlled studies reported that
primaquine 15 mg daily for 5 days was effective in preventing
P. vivax relapse.72–74 However, controlled studies have shown
15 mg daily for 5 days has no therapeutic efficacy and, there-
fore, this duration of treatment should not be used.75–79
If a dose of primaquine is missed during PART, the
course should be continued until all doses are taken (B-III).
Because total cumulative dose is important in determining
efficacy of primaquine treatment,68 it is not necessary to re-
start PART.
PHARMACOKINETICS
In five fasted, healthy volunteers who were given oral pri-
maquine along with an intravenous dose of radiolabeled pri-
maquine, absorption was nearly complete,80,81 with a mean
bioavailability of 96%.80 Areas under the concentration curve
after doses of 15, 30, and 45 mg were linear, suggesting first-
order kinetics. The mean tmax was 3 ± 1 hours (2- to 3-hour
range) in healthy volunteers given a 45-mg dose. The mean
Cmax in these subjects was 153 ± 24 ng/mL (range, 131–180
ng/mL). In Thai volunteers given a 14-day regimen of pri-
maquine, there was no difference in tmax and Cmax after the
first and last doses.82 Among Indian patients being treated for
P. vivax malaria, the mean tmax and Cmax were similar to
values in healthy subjects.83
Primaquine is extensively distributed in tissues, with the
mean apparent volume of distribution ranging from 200 to
300 L.80,83,84 Unlike chloroquine, primaquine does not accu-
mulate in red blood cells. In one study, the mean whole blood
to plasma concentration ratio of primaquine was 0.81.80 Pri-
maquine binds preferentially to the acute phase reactant pro-
tein alpha-1-glycoprotein, and the amount of that protein in
blood may alter the distribution of free primaquine.85
The metabolism of primaquine in humans and various ani-
mal systems has been reviewed.86 In human microsomes in
vitro, primaquine was metabolized primarily to carboxypri-
maquine.80,87,88 The time to peak carboxyprimaquine levels
in plasma was 3–12 hours, with the Cmax being 10 times higher
than the parent compound. Carboxyprimaquine does not ac-
cumulate during 14 days of dosing. Primaquine is also me-
tabolized to a number of other identified and unidentified
metabolites that are detectable in urine and plasma. Only
∼1–4% of primaquine is eliminated as parent compound in
urine.80,89
Primaquine has been shown to decrease the clearance of
antipyrene, resulting in an increase in its half-life.90 Anti-
pyrene is a general probe for the hepatic cytochrome P-450
(CYP).91 If there is no change in antipyrene metabolism with
the drug of interest, there are likely to be no significant CYP
interactions. Recent studies show that primaquine induces the
CYP 1A2 enzyme in both recombinant and microsomal in
vitro systems.87,92,93 This induction could decrease the plasma
concentrations of drugs that are metabolized by CYP 1A2,
with a potential for decreased efficacy.94,95 Examples of com-
monly prescribed drugs that are metabolized by CYP 1A2 are
tricyclic antidepressants; antipsychotics (e.g., clozapine and
haloperidol); and benzodiazepines, caffeine, propranolol, the-
ophylline, and warfarin (http://medicine.iupui.edu/flockhart/
table.htm). The clinical significance of this potential interac-
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tion is not known; however, prescribing primaquine for pro-
phylaxis concurrently with drugs that are metabolized by
CYP 1A2, warfarin should be undertaken with caution or
avoided. Because there is no other drug for PART or radical
cure, clinicians should weigh the risks and benefits of using
primaquine. Mefloquine inhibits metabolism of primaquine
(and vice versa) in an in vitro microsome system, but the
clinical relevance of this interaction is not known.96
In healthy volunteers, the half-life (elimination) of pri-
maquine was 7 ± 4 hours (2- to 12-hour range).84 In another
study, it was 6 ± 2 hours.80 In healthy Thai volunteers, it was
4 ± 1 hours after a 14-day dosing.82 Similar estimates were
observed in patients with P. vivax malaria and in those with
G6PD deficiency.83
Although liver or renal disease could theoretically delay
metabolism or excretion of primaquine,97 there are no data
available to suggest optimal dosing adjustments in individuals
with hepatic or renal dysfunction. Current recommendations
are to not change dosing of primaquine in patients with renal
insufficiency or renal failure.98
Virtually all pharmacokinetic studies of primaquine have
been conducted on fasted human subjects. Little is known of
the effect of food on primaquine, with the exception of the
apparent ability of food to greatly diminish the risk of gas-
trointestinal upset. In an uncontrolled study involving sub-
jects who were fed 15 minutes after primaquine dosing,99 the
Cmax and area under the curve for primaquine were substan-
tially higher in fed subjects compared with subjects with ma-
laria or healthy Thai or white subjects. Randomized studies of
primaquine pharmacokinetics in fed versus fasted subjects
are needed. Nonetheless, most authorities recommend that
primaquine be administered with food or after a meal to
avoid gastrointestinal adverse events, especially abdominal
cramps.38,97,100
COMPLIANCE
No published study has examined compliance with a daily
regimen of primaquine for prophylaxis. Studies of suppressive
prophylaxis using other anti-malarials reveal that individuals
are frequently non-compliant with doses that should be taken
after leaving the malarious area.101–103 Full compliance with
the 2-week regimen of PART with primaquine in repatriated
military populations has ranged from 4% to 80%.104–106 The
requirement for only 1 week of post-exposure prophylaxis
when primaquine is used for primary prophylaxis should im-
prove patient compliance. Given the importance of dosing
within 24–72 hours after challenge (described previously),8
compliance with daily dosing of primaquine may prove an
important determinant of effectiveness, especially in areas of
very high risk.107
SAFETY/TOLERABILITY
The most serious adverse event linked to primaquine is an
acute intravascular hemolysis in people having an inborn de-
ficiency of G6PD.108 The most common adverse event in
G6PD-normal, non-pregnant individuals is gastrointestinal
upset if primaquine is ingested on an empty stomach.13 A
mild, self-limited, and asymptomatic methemoglobinemia oc-
curs in most people receiving primaquine. Clinical studies of
subjects receiving therapeutic or prophylactic regimens do
not corroborate early studies suggesting that primaquine
causes cellular immune suppression and leucopenia.
G6PD deficiency. Primaquine causes hemolytic anemia in
people with an inborn deficiency of G6PD. The severity of
hemolytic anemia seems to be related to primaquine dosing
and the variant of the G6PD enzyme, i.e., the degree of G6PD
deficiency. More than 300 allelic variants are known. These
are divided into classes based on level of residual enzyme
activity in red blood cells.108 The most common variant occurs
in persons of African descent (A−) who have a mild impair-
ment of G6PD activity (usually > 10% activity), and in whom
primaquine causes a mild hemolytic anemia limited to senes-
cent red blood cells.109 Other ethnic groups, including whites
and Asians, may have a more severe form of G6PD deficiency
(typically < 10% residual activity) that can result in progres-
sive, potentially fatal hemoglobinemia and hemoglobinuria
after treatment with standard doses of primaquine.97 Preva-
lence of G6PD deficiency is relatively common among
Africans (1–20%) and typically rare in other ethnic groups
(< 1%).
In persons with normal levels of G6PD, hemolysis is not
observed. One study reported no noticeable hemolysis among
Thai patients with normal levels of G6PD taking 22.5 mg of
primaquine daily for 14 days.47 The same was true among 99
G6PD-normal Javanese adults receiving 30 mg primaquine
daily for 20 weeks.16
In persons with mild impairment of G6PD activity, hemo-
lysis starts 3–4 days after the first dose of primaquine and lasts
∼7 days. Recovery with reticulocytosis occurs even if 30 mg
primaquine daily dosing is continued because reticulocytes
and the remaining red cells are relatively resistant to pri-
maquine-induced hemolysis.40
A 45-mg weekly dose of primaquine does not cause clini-
cally significant hemolysis in people having the A− variant,
and this was the basis for developing the 45 mg/wk for 8
weeks regimen for prevention of relapse.40 Eight subjects
with the A− variant were administered 45 mg weekly for 8
weeks and developed only mild, asymptomatic hemolysis (he-
moglobin decrease range, 0.5–2.5 g/dL).110
Investigators in Burma treated 20 patients who were hem-
izygous for mild deficiency and 2 patients hemizygous for
severe deficiency with either one dose of primaquine (45 mg;
9 patients with mild deficiency and 1 severe) or 45 mg of
primaquine weekly for 8 weeks (11 mild deficiency and 1
severe).69 Although the numbers were small, they found no
significant change in methemoglobinemia compared with the
patients with normal G6PD levels and no clinical signs of
drug-induced hemolysis. In a clinical trial involving seven
G6PD-deficient Thai soldiers (with variable residual enzyme
activity), hemolysis after a single dose of 45 mg primaquine
was mild and affected 8–18% of red cells.111 However, severe
hemolysis has been reported after the administration of a
single 45-mg dose in whites112 and in patients in Vanuatu with
severe deficiency.113
The degree of hemolysis in other variants of G6PD exposed
to standard primaquine therapy (15–30 mg daily) varies
widely. In Burma, two healthy volunteers infused with G6PD-
deficient red blood cells and given 15 mg daily for 14 days lost
34–48% of those cells.114 Among 441 patients treated with
primaquine (15 mg/d for 14 days) for P. vivax in Thailand, 13
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were G6PD-deficient.115 These patients developed only
slightly lower hematocrits. Primaquine induced hemolysis in
three other Thai subjects (29% residual activity in one and
2–10% in the other two), with their hematocrits decreasing by
9–13%.116
The Mediterranean B− variant of G6PD deficiency occurs
in individuals whose ethnic background includes ancestors
from the Mediterranean basin or west Asia. Individuals with
the B− variant have minimal or no detectable residual G6PD
enzyme activity.97,117 Administration of primaquine to people
with the B− variant risks severe, potentially life-threatening
hemolysis. A randomized, open-label trial in Malaysian
Borneo compared chloroquine, chloroquine-primaquine, and
pyrimethamine-sulfadoxine for treatment of individuals with
acute malaria. Sixteen subjects with severe G6PD deficiency
were unwittingly treated with chloroquine-primaquine (1.5 g
chloroquine and 15 mg/d primaquine for 3 days for P. falci-
parum infection or for 14 days for P. vivax infection). Seven
subjects experienced hemolytic anemia, and five of them re-
quired transfusion with one to two units of blood. Among the
transfused subjects, two suffered renal failure, with one re-
quiring peritoneal dialysis.118 Severe hemolysis with renal
failure requiring dialysis was reported in a Thai soldier after
three 15-mg doses of primaquine.119 Severe hemolysis oc-
curred among G6PD-deficient Sardinians given a single dose
of 30 mg primaquine.120
Because of the risk of hemolysis in G6PD-deficient indi-
viduals, laboratory determination of the patient’s G6PD sta-
tus must be performed before prescribing primaquine. This
can be done with either a quantitative determination of the
enzyme level or a qualitative screening test.121 Quantitative
assays will identify nearly all persons with a G6PD deficiency;
however, they are more expensive to perform and are not
necessary to obtain for the purposes of determining whether
primaquine may be safely administered. Qualitative screening
tests are sufficient to identify individuals with a G6PD defi-
ciency with the following exceptions: recent hemolysis in a
person with one of the milder G6PD deficiency variants and
some women who are heterozygous for the gene and have
mild deficiency. In cases of primaquine-induced hemolysis,
older erythrocytes are selectively hemolyzed, leaving younger
cells with near normal levels of G6PD.108,121 Nevertheless,
qualitative tests will identify persons who will be at risk from
taking primaquine, and if the test is abnormal, the drug
should not be used for prophylaxis.
Persons deficient in the enzyme NADH methemoglobin
reductase are extremely sensitive to hemoglobin-oxidizing
agents such as primaquine.122,123 This enzymatic deficiency is
much rarer than G6PD deficiency and is associated with met-
hemoglobinemia.
Methemoglobinemia. Methemoglobinemia (> 1% methe-
moglobin) usually occurs with therapeutic or prophylactic
dosing regimens. One study reported mean/maximum methe-
moglobin levels of 6%/9%, 10%/18%, and 11%/18% among
persons receiving 15, 22.5, and 30 mg of primaquine, respec-
tively, for 14 days.38 Another study (N  30) of primaquine
(15 mg for 14 days) reported mean methemoglobin levels of
5.9% (range, 1.3–19.3%) at 14 days; there were no reported
symptoms relating to the methemoglobinemia.124 Two weeks
after the last dose, the highest methemoglobin level (19.3%)
decreased to 2.3%. In other studies, methemoglobin levels as
high as 18% have been reported among persons taking 22.5
mg daily for 14 days,125 and in persons in a 20-week trial, the
highest methemoglobin level recorded on the last day of pro-
phylaxis was 8.5%.16 In this latter study, the authors deter-
mined that the risk of methemoglobinemia did not increase
with the duration of administration of primaquine and that it
resolved within 2 weeks after cessation of dosing.16 Among
persons taking 0.5 mg/kg/d (adult dose equivalent 30 mg/d)
primaquine for 1 year, no negative impact on the complete
blood count or renal or hepatic function was seen; methemo-
globinemia levels at week 50 ranged from 1.4% to 13%
(mean, 5.8%).13
Cyanosis can occur when the methemoglobin level exceeds
15–20 g/L of blood (∼10% of the normal level of hemoglo-
bin),97 although cyanosis may be seen in fair-skinned persons
at methemoglobin levels of < 6%.122 The clinical use of spe-
cific methemoglobinemia percentages is unclear. In some
studies, methemoglobinemia values of up to 20% are often
asymptomatic126 and may be well-tolerated up to levels of
25%.97 Most authorities have argued that, whereas patients
tolerate levels < 10% quite well, persons with levels of 20%
are likely to be symptomatic. Others suspect that the presence
or absence of symptoms depends not just on absolute per-
centage of methemoglobinemia, but also the rapidity with
which methemoglobinemia occurs.122
Symptoms may develop at lower methemoglobin levels in
persons with underlying pulmonary disease and limited pul-
monary reserve.127 No study has documented clinically ap-
parent methemoglobinemia after therapeutic or prophylactic
regimens of primaquine, except in patients having an inborn
deficiency of methemoglobin reductase.97,124 In summary,
primaquine-induced methemoglobinemia, although almost
universal with clinical doses, seems to be mild, self-limited,
and tolerated without symptoms or signs of cyanosis in oth-
erwise healthy people.
Gastrointestinal adverse events. The risk of ADRs with pri-
maquine increases with increasing doses of the drug (Tables 2
and 3).97 In a large study (N  699) evaluating doses of 15
mg/d or less of primaquine in adults, ADRs occurred no more
frequently than with placebo.38 Among fasted persons receiv-
ing 22.5–30 mg/d, 10–12% reported mild to moderate abdomi-
nal cramps.38 Individuals taking 120 mg daily reported mod-
erate abdominal cramps and nausea.34 Administration of 240
mg/d resulted in moderate to intolerably severe abdominal
cramps.34 These early investigators noted that the risk of gas-
trointestinal upset at any dose of primaquine essentially dis-
appeared when the drug was administered with food.38
A randomized, double-blind placebo-controlled trial giving
fed adult subjects 30 mg daily for 1 year found no difference
in the number or type of complaints between subjects receiv-
ing primaquine compared with those receiving placebo.13 Fed
Kenyan children dosed with 15 mg daily for 11 weeks toler-
ated primaquine as well as placebo.11 Primaquine (0.5 mg/kg
dose) for 18–20 weeks given every other day with a snack
resulted in fewer ADRs than weekly chloroquine 5 mg/kg
(300 mg in an adult) among Javanese children and adults in
Papua.100 In another randomized, placebo-controlled trial in
Indonesian adults, only headache, cough, and sore throat
were reported significantly more frequently in recipients of
primaquine compared with those taking placebo.16 Among
122 Colombian soldiers, epigastric pain, abdominal pain, and
other gastrointestinal symptoms occurred among nine recipi-
ents (7.4%) of primaquine (30 mg daily) compared with 1 of
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54 subjects receiving placebo (1.9%; P  not significant).14
Taken with a snack or meal, daily primaquine for prophylaxis
(0.5 mg/kg/d) seems to be as well tolerated as placebo.
Neuropsychiatric adverse events. Psychomotor effects have
not been noted,128 and neuropsychiatric changes seem to be
rare, with only a single case report of depression and psycho-
sis after primaquine use.129
Immune effects. Laboratory studies suggest that pri-
maquine inhibits lymphocyte proliferative responses in
vitro.130,131 These findings served as the basis of warnings that
primaquine therapy may be linked to clinically significant im-
munosuppression.97 Although inhibition of lymphocyte pro-
liferation has been observed in vitro,132 in vivo studies in
mice133 and monkeys did not disclose similar findings.132,134
Primaquine did not inhibit human natural killer cell toxicity in
vitro.135 Moreover, clinical studies do not corroborate immu-
nosuppression by primaquine. In subjects receiving pri-
maquine, Fryauff and others136,137 showed normal to elevated
cellular immune responses to tetanus toxin epitopes and hu-
moral immune responses to tetanus-diphtheria vaccine. Re-
peated testing of lymphocyte function during a year-long
chemoprophylaxis trial produced no evidence of immune sup-
pression or disturbance induced by moderate or long-term
daily primaquine.138,139 Moreover, long-term use of pri-
maquine did not effect intestinal helminth and protozoal
parasite burdens.140
An early report linked neutropenia to a 2-week course of
primaquine therapy (dose not stated) among patients with
rheumatoid arthritis.141 However, none of 338 men given 15–
30 mg of primaquine daily for 14 days showed evidence of
leucopenia; 6%, 21%, and 4% of subjects who received pri-
maquine 15, 22.5, and 30 mg, respectively developed leuko-
cytosis (10,000–17,000 WBC/mm3).38 Other investigators
have also observed leukocytosis42 or no alteration in white
cell counts.39,142 High-dose primaquine (120–240 mg daily)
has been associated with neutropenia.34,38,142 Based on this
information, some authors have advised against its use in per-
sons being treated with myelosuppressive drugs or who suffer
from concurrent conditions characterized by bone marrow
depression.97 However, more recent clinical trials using pro-
longed daily primaquine dosing that included monitoring of
complete blood counts (as well as hepatic and renal function
testing) showed no evidence of toxicity.13,16
CONTRAINDICATIONS
Primaquine is contraindicated for prophylaxis in all persons
with G6PD deficiency and in pregnant women (because of the
risk of acute hemolysis in the fetus with unknown G6PD sta-
tus). The packaging label states that primaquine is also con-
traindicated in persons with illnesses manifest by a tendency
to granulocytopenia, e.g., lupus erythematosus and rheuma-
toid arthritis (although the rationale for this warning is sus-
pect; see discussion above). The label further warns against
concurrent treatment with other potentially hemolytic drugs
or depressants of the myeloid elements of the bone mar-
row.143 The label warns that quinacrine hydrochloride poten-
tiates the toxicity of primaquine, and these drugs should not
be administered together.
Persons deficient in the enzyme NADH methemoglobin
reductase are extremely sensitive to hemoglobin-oxidizing
agents such as primaquine.122,123 Individuals with minimal
cardiopulmonary reserve may poorly tolerate the methemo-
globinemia induced by primaquine. Persons allergic to io-
doquinol, a chemically related 8-aminoquinolone, may be al-
lergic to primaquine.144
DURATION OF USE
Few studies have examined the long-term use of pri-
maquine for prophylaxis. One study reported administration
of 0.5 mg/kg daily for 52 weeks with no long-term toxicity
detected.13 Similar results were reported in studies that evalu-
TABLE 2
Severe ADRs associated with primaquine use
Study location/design
Duration of
dosing Dosing regimen
Number of severe
ADRs/number at risk Adverse event
Discontinued because
of severe ADRs
USA/experimental challenge34 14 d 15–240 mg/d – Abdominal cramping NA
USA/experimental challenge38 6–14 d 15–120 mg/d 0/89 None None
USA/experimental challenge67 7 d 60 mg/d 1/11 Abdominal cramping,
vomiting, cyanosis
SADR attributed to
another substance
in 1 subject
Papua/randomized placebo-controlled16 20 wk 30 mg/d 0/97 None None
Papua/randomized double blind,
placebo-controlled13
52 wk 30 mg/d 0/126 None None
Kenya/randomized double-blind,
placebo-controlled11
11 wk 15 mg/d 0/32 None None
Colombia/randomized, double-blind,
placebo-controlled14
16 wk 30 mg/d 3/122 Epigastric pain,
vomiting, abdominal
pain
3%
Ethiopia/prospective observational19 2–3 wk 15–30 mg/d 1/106 Nausea, vomiting 1%
Papua/open clinical trial100 16–19 wk 0.5 mg/kg every
other day
0/45 None None
Thailand/open randomized clinical
trial47
14 d 15 or 22.5 mg/d 0/167 None None
Colombia/randomized, double-blind
placebo-controlled14
17 wk Primaquine 30
mg/d + 300 mg
chloroquine/wk
2/100 Vomiting 2%
ADRs, adverse drug reactions; NA, not available.
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ated 11- and 20-week regimens of primaquine.11,14,16,100 Two
studies examined toxicity of 30 mg weekly to twice weekly for
9–12 months and found no evidence of long term toxicity.2,38
No data are available on use of primaquine for > 1 year.
THERAPEUTIC INDEX/OVERDOSE
Primaquine has a chemotherapeutic index1 of 10.34 High
doses, 60–240 mg/d, lead to toxic reactions including abdomi-
nal cramps, nausea, and headache, and are also associated
with cyanosis from methemoglobinemia.145
DRUG INTERACTIONS
Some antipyretics, analgesics, and sulfonamides may pre-
cipitate hemolysis in G6PD-deficient persons and compound
hemolysis induced by primaquine.97,109,117 Methemoglobine-
mia can be induced in HIV-infected individuals being treated
for or prophylaxed against Pneumocystis jiroveci pneumonia
with primaquine 30 mg/d, especially in those currently or re-
cently taking dapsone.127,146–149
Primaquine can be administered with oral contraceptives
with no apparent interaction or interference with hepatic me-
tabolism of the contraceptives.150 Clinical trials have shown
that primaquine does not inhibit humoral or cellular im-
mune responses after tetanus or tetanus/diphtheria vaccina-
tion.136,137
Quinacrine seems to potentiate the toxicity of anti-malarial
agents that are structurally related to primaquine, and the
concomitant use of quinacrine and primaquine is not recom-
mended.144,151
SPECIAL POPULATIONS
The pharmacokinetics of primaquine have not been studied
in children, pregnant women or patients with renal or hepatic
dysfunction.152
Children. Although few studies document the safety and
tolerability of primaquine in children, the drug has been used
1 Chemotherapeutic index is the ratio of the largest tolerated dose
divided by the smallest effective dose (in this case the dose capable of
preventing nearly all relapses).
TABLE 3
Mild to moderate ADRs associated with primaquine use
Study location/design Sample size dose duration Most frequent ADRs Comparator ADR risk with primaquine use
USA/experimental
challenge34
N  45
15–240 mg/d
1–14 d
Abdominal cramping,
anorexia, nausea,
vomiting
None In fasted subjects, risk
related to dose.
In fed subjects, no GI
complaints
USA/experimental
challenge38
N  89
15–120 mg/d
6–14 d
Abdominal cramping:
15 mg—0%
22.5 mg—7%
30 mg—4%
60 mg—33%
120 mg—100%
None In fasted subjects, risk
related to dose
USA/experimental
challenge67
N  11
60 mg/d
7 d
Nausea, abdominal
cramping
None 2 subjects with moderate
ADRs
Papua/randomized
placebo-controlled16
N  97
30 mg/d
20 wk
Headache, abdominal
pain, cough, nausea,
dizziness
Placebo None higher than placebo
Papua/randomized
double-blind,
placebo-controlled13
N  126
30 mg/d
52 wk
Headache, abdominal
pain, URI symptoms,
itching/rash, fatigue
Placebo Cough and itch higher than
placebo
Kenya/randomized
double-blind,
placebo-controlled11
N  32
15 mg/d
11 wk
Headache, abdominal
pain, fever, nausea,
diarrhea
Placebo, mefloquine,
doxycycline, chloroquine
+ proguanil
None higher than placebo
Colombia/randomized,
double-blind
placebo-controlled14
N  122
30 mg/d
16 wk
Gastrointestinal Placebo 7.5% primaquine vs. 2%
placebo
Ethiopia/prospective
observational19
N  106
30 mg/d
2–3 wk
Vomiting Mefloquine, doxycycline 1 of 106 subjects discontinued
primaquine secondary to
vomiting. 1 of 19 taking
doxycycline discontinued
Papua/open clinical
trial100
N  45
0.5 mg/kg/every other day
16–19 weeks
Headache, fever,
diarrhea, abdominal
pain, vomiting
Chloroquine None higher than that
associated with chloroquine
use
Thailand/open
randomized clinical
trial47
N  81 (15 mg/day)
N  86 (22.5 mg/day)
14 d
Not reported Not reported None noted
Colombia/randomized,
double-blind
placebo-controlled14
N  100
30 mg/d (+300 mg
chloroquine/wk)
17 wk
Gastrointestinal Placebo
ADRs, adverse drug reactions.
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in children for > 50 years. Weiss and others11 reported good
tolerance with primaquine (0.5 mg/kg/d) for primary prophy-
laxis in Kenyan children 9–14 years of age. In another study of
primary prophylaxis,100 Baird and others included children as
young as 7 years of age.
The lower age or weight limit of primaquine use has not
been determined. Some public health authorities recommend
that primaquine not be given to children < 4 years of age
because of the risk of hemolysis,153 and others recommend it
not be used in children < 1 year old.154,155 Some investigators
avoid administering it to young children for radical cure of P.
vivax.156 In some malaria control programs, it is not used for
children < 1 year of age79,157 or for those < 3158 or 6 months
of age in other programs.159,160 In Vanuatu, it is not given to
children who weigh < 9 kg.161 The American Academy of
Pediatrics does not list a lower age limit for primaquine
use,162 nor do some other authors163 and public health au-
thorities.5,6,164 Those who recommend against using pri-
maquine in children do not cite data supporting their view. In
vitro work does suggest, however, that neonatal erythrocytes
may undergo endocytosis in response to primaquine (as well
as to other drugs).165,166
In summary, limited data support the safety and efficacy of
primaquine for primary prophylaxis in children 7 years of age
and older. There is no evidence to suggest that children of any
age who are not deficient in G6PD do not tolerate the drug,
although data are lacking. Because the use of primaquine
requires performance of a blood test to check G6PD level,
and because of the requirement for daily administration of
the drug, its use in small children may be problematic. There
are other efficacious and better-studied drugs that can be
administered to children to prevent malaria, including drugs
that require once weekly administration and that do not re-
quire phlebotomy. Primaquine could, therefore, be consid-
ered as an alternative for children for whom other malaria
chemoprophylactic regimens would either be ineffective or
contraindicated.
Pregnant women. Primaquine may cause hemolysis and hy-
drops fetalis in fetuses, and because the G6PD status of the
fetus is rarely known with certainty, administration of pri-
maquine is contraindicated during pregnancy irrespective of
the mother’s G6PD status.167,168 Pregnant women who need
primaquine for radical cure of P. vivax or P. ovale malaria
should be treated after they have delivered and may be main-
tained on weekly chloroquine until delivery.
No data are available on primaquine use in breastfeeding
women169 or excretion of primaquine in breast milk. As a
precaution, breast-feeding infants should be tested for G6PD
deficiency before primaquine is given to the mother.5
COST
For a 14-day trip to a malarious area, including doses taken
before, during, and after malaria exposure, the estimated
drug costs for prophylaxis are shown in Table 4.170 These
costs do not include testing for G6PD deficiency for pri-
maquine, nor do they include using primaquine for PART
when chloroquine, doxycycline, mefloquine, or atovaquone/
proguanil are given. The estimated cost for G6PD testing is
$25.00.170
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